Exchange listing deficiency and compliance notices under 8-K Item 3.01.
AMERICAN REBEL HOLDINGS INC received a nasdaq compliance regained notice regarding late filing (rules 5250(c)(1)).
“February 10, 2025, the Company received a written notification from the Staff indicating that the Company had regained compliance with the periodic filing requirement under Nasdaq Listing Rules.”
Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that, for the previous 30 consecutive business days, the bid price for the Company’s common stock had closed below the minimum $1.00 per share requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Bid Price Requirement”). The Notice has no effect at this time on the Company’s common stock, which continues to trade on The Nasdaq”
Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 7, 2025, Applied Therapeutics, Inc. (the “ Company ”) received written notification (the “ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days, the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Global Market, pursuant to Nasdaq Listing Rule 5450(a)(1) (the “ Bid Price Requirement ”). The Notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Global Market. Pursuant”
NSTS Bancorp, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1), 5605(a)(2)).
“February 7, 2025, the Company received a letter from Nasdaq confirming that, due to Mr. Bond’s death, the Company has temporarily fallen out of compliance with the requirements of Rule 5605(b)(1) of the Nasdaq listing standards. In accordance with Rule 5605(b)(1)(A) of the Nasdaq listing standards, the Company has until the earlier of its next annual stockholders’ meeting or December 21, 2025 to regain compliance, or if the Company’s next annual stockholders’ meeting is held before June 19, 2025, then the Company must evidence compliance no later than June 19, 2025. Prior to the end of the cur”
Global Interactive Technologies, Inc. received a nasdaq delisting notice notice.
“February 5, 2025, Global Interactive Technologies, Inc., a Delaware corporation (the “ Company ”), received a notification letter (the “ Determination Letter ”) from the staff at the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”). On February 10, 2025, the Company issued a press release announcing its receipt of the Determination Letter. The press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.”
Applied Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“February 7, 2025, Applied Therapeutics, Inc. (the “ Company ”) received written notification (the “ Notice ”) from the Nasdaq Stock Market (“ Nasdaq ”) that, because the closing bid price for the Company’s common stock h”
NSTS Bancorp, Inc. received a nasdaq deficiency notice notice regarding board independence (rules 5605(b)(1)).
“February 7, 2025, the Company received a letter from Nasdaq confirming that, due to Mr. Bond’s death, the Company has temporarily fallen out of compliance with the requirements of Rule 5605(b)(1) of the Nasdaq listing st”
Processa Pharmaceuticals, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 4, 2025, Processa Pharmaceuticals, Inc. (the “Company”) received a letter (the “Notice”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company t”
REGIONAL HEALTH PROPERTIES, INC received a nyse_american delisting notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii), 1009(a)).
“February 3, 2025, Regional received a letter from the Panel (the “Letter”), that based upon the material and information presented to the Panel, discussion that occurred at the hearing and analysis of the Exchange rules and the Company Guide, the Panel unanimously determined to affirm the Staff’s decision to initiate delisting proceedings. Regional may request, as provided by Section 1205 of the Company Guide, that the full Committee reconsider the decision of the Panel. The request for the review and the required fee must be made in writing and received within 15 calendar days from the date o”
Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common stock would be delisted from The Nasdaq Capital Market unless the Company appeals the Staff’s delisting determination by requesting a hearing before the Nasdaq Hearings Panel (the “Panel”). The Company’s request for a hearing will stay any further delisting action by the Staff pending the ultimate outcome of the hearing. The Company’s common stock will remain listed and eligible”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 30 consecutive business days (December 23, 2024 through February 6, 2025), the Company’s common stock did not maintain a minimum closing bid price of $1.00 (“Minimum Bid Price Requirement”) per share as required by Nasdaq Listing Rule 5550(a)(2). The notice has no immediate effect on the listing or trading of the Company’s common stock and the common stock will continue to trade”
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Company an additional 180 calendar days, or until August 4, 2025, to regain compliance with the minimum closing bid price requirement for continued listing on The Nasdaq Capital Market under Nasdaq Listing Rule 5550(a)(2) (the “Rule”). In connection with the Extension Notice, the listing of the Company’s common stock was transferred from the Nasdaq Global Market to the Nasdaq Capi”
BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2) (the “Rule”) because the Company has not maintained a minimum closing bid price of the Company’s common stock of at least $1.00 per share for the last 30 consecutive business days. The Notice has no immediate effect on the listing or trading of the Company’s securities. The Company has 180 calendar days from the date of the Notice, or until Aug”
HCW Biologics Inc. received a nasdaq delisting notice notice regarding market value (rules 5450(b)(2)(C)).
“February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclosed on December 23, 2024, the Company received written notice from the Staff regarding for the 30 consecutive business days ended June 17, 2024, the Company’s market value of listed securities (“MVLS”) closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company was g”
HCW Biologics Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5810(c)(3)(A)).
“February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclosed on December 23, 2024, the Company received written notice from the Staff regarding for the 30 consecutive business days ended June 17, 2024, the Company’s market value of listed securities (“MVLS”) closed below the $50,000,000 MVLS threshold required for continued listing on the Nasdaq Global Market under Nasdaq Listing Rule 5450(b)(3)(A) (the “MVLS Rule”). The Company was g”
AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
“recent fiscal years (the “Minimum Requirement”), as defined in Section 1003(a)(i) of the Company Guide. Pursuant to the Notice, the Company reported a stockholders’ deficit of $32.1 million at September 30, 2024 and has had losses in the two most recent fiscal years ended December 31, 2023 based on the Company’s Annual Report on Form 10-K/A filed with the U.S.”
ALPHA MODUS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value.
“February 5, 2025, Alpha Modus Holdings, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company no longer meets the minimum market value of listed securities (“ MVLS ”) of $50,000,000 required by Nasdaq’s Listing Rules (the “ Rules ”). The Notice has no immediate effect on the listing or trading of the Company’s securities, except that an indicator will be displayed with quotation information related to the Company’s securities on NASDAQ.com and NASDAQTrader.com and may be d”
Evergreen Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).
“February 3, 2025, Evergreen Corporation (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not comply with the minimum 400 total shareholders requirement for continued listing on the Nasdaq Global Market, and had failed to regain compliance with Nasdaq Listing Rule 5450(a)(2) during the extension period which ended on January 28, 2025. The Company has until February 10, 2025 to request a hearing before the Nasdaq Hearings Panel (the “Panel”). If the Company does not request a hearing before the Panel by that date, trading in its securitie”
ECD Automotive Design, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 5, 2025, ECD Automotive Design Inc., a Delaware corporation (the “Company”), received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s common stock failed to maintain a minimum bid price of $1 per share, based upon the closing bid price for the last 30 consecutive business days. Accordingly the Company failed to comply with Rule 5550(a)(2) the Nasdaq Listing Rules (the “Rules”). The Notice has no immediate effect on the listing of the Company’s common stock on Nasdaq. Rule 5810(c)(3)(A) provides the Company a compliance period of 180 cale”
ECD Automotive Design, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 5, 2025, ECD Automotive Design Inc., a Delaware corporation (the “Company”), received a notice (the “Notice”) from The Nasdaq Stock Market LLC (“Nasdaq”), stating that the Company’s common stock failed to mainta”
ALPHA MODUS HOLDINGS, INC. received a nasdaq deficiency notice notice regarding market value.
“February 5, 2025, Alpha Modus Holdings, Inc. (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department of The Nasdaq Stock Market (“ Nasdaq ”) indicating that the Company no”
Evergreen Corp received a nasdaq deficiency notice notice regarding shareholders (rules 5450(a)(2)).
“February 3, 2025, Evergreen Corporation (the “Company”) received a letter from The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company did not comply with the minimum 400 total shareholders requirement for contin”
AEON Biopharma, Inc. received a nyse_american noncompliance notice notice regarding stockholders equity (rules 1003(a)(i)).
“February 3, 2025, AEON Biopharma, Inc. (the “Company” or “AEON”) received a written notice of non-compliance (the “Notice”) from the NYSE American LLC (the “NYSE American”) stating that the Company is not in compliance w”
HCW Biologics Inc. received a nasdaq delisting notice notice regarding other (rules 5810(c)(3)(A), 5450(b)(2)).
“February 5, 2025, the Staff notified the Company that its securities were subject to delisting from Nasdaq unless the Company timely requests a hearing before the Nasdaq Hearing Panel (the “Panel”). As previously disclos”
BioAtla, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 6, 2025, BioAtla, Inc. (the “Company”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) stating that the Company is not in compliance wi”
IN8BIO, INC. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2)).
“February 5, 2025, IN8bio, Inc. (the “Company”) received a notice (the “Extension Notice”) from the Listing Qualifications Department of the Nasdaq Stock Market (“Nasdaq”) informing the Company that Nasdaq granted the Com”
bioAffinity Technologies, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 7, 2025, bioAffinity Technologies, Inc. (the “Company”) received written notice from the Listing Qualifications Department of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that for the preceding 3”
Solana Co received a nasdaq delisting notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 7, 2025, the Company received a letter from the Staff indicating the Company’s continued non-compliance with the Minimum Bid Price Requirement. The letter further informed the Company that the Company’s common s”
REGIONAL HEALTH PROPERTIES, INC received a nyse_american delisting notice notice regarding stockholders equity (rules 1003(a)(i), 1003(a)(ii)).
“February 3, 2025, Regional received a letter from the Panel (the “Letter”), that based upon the material and information presented to the Panel, discussion that occurred at the hearing and analysis of the Exchange rules”
Cyngn Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)(iv)).
“February 6, 2025, Cyngn Inc., a Delaware corporation (the “Company”) received a letter (the “Minimum Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (“Nasdaq”), notifying the Company that it was not in compliance with Nasdaq Listing Rule 5550(a)(2) which requires listed companies to maintain a minimum bid price of $1.00 per share (the “Minimum Bid Price Requirement”). Normally, a company would be afforded a 180-calendar day period to demonstrate compliance with the Minimum Bid Price Requirement. However, pursuant to Listing”
Cyngn Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
“February 6, 2025, Cyngn Inc., a Delaware corporation (the “Company”) received a letter (the “Minimum Bid Price Deficiency Letter”) from the Listing Qualifications Department (the “Staff”) of The Nasdaq Stock Market LLC (”
Beyond Air, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“listing of the Company’s common stock, which will continue to be listed and traded on the Nasdaq Capital Market, subject to the Company’s compliance with the other listing requirements of the Nasdaq Capital Market. Although the Company will use all reasonable efforts to achieve compliance with Rule 5550(a)(2), there can be no assurance that the Company will be able to regain compliance with that rule or will otherwise be in compliance with other listing criteria of the Nasdaq Capital Market.”
STRYVE FOODS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“February 4, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified Stryve Foods, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s Class A common stock and warrants and that trading of the Company’s securities will be suspended at the open of trading on February 6, 2025. As previously reported, on December 19, 2024, the Company was granted an extension until January 31, 2025 from a Panel to regain compliance with Nasdaq’s continued listing rules and demonstrate long-term compliance with the Listing Rule 5550(b)(1), which requires listed iss”
Oklo Inc. received a nyse noncompliance notice notice regarding audit committee (rules 303A.07(a), 303A.12(b)).
“February 5, 2025, the Company received an official notice of non-compliance from the NYSE (the “NYSE Notice”). The NYSE Notice does not have any immediate effect on the listing of the Company’s common stock, which remains trading under the trading symbol “OKLO.” The Board intends to appoint a new independent director, duly qualified for service on the Audit Committee, as soon as practicable. SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Oklo Inc.”
Global Star Acquisition Inc. received a nasdaq delisting notice notice regarding shareholders (rules 5450(a)(2)).
“lobal Market. Under Nasdaq Listing Rules, the Company had 45 calendar days or until January 9, 2025, to submit a plan to regain compliance with Rule 5450(b)(2)(B). Separately, on August 1, 2024, we received a notice from the Staff notifying us that the Company is not in compliance with Listing Rule 5450(a)(2) (the “Minimum Public Holders Rule”), which requires the Company to have at least 400 total holders for continued listing on The Nasdaq Global Market. We submitted the plan to regain compliance in a timely manner, and Nasdaq advised the Company that it had determined to grant the Company a”
Global Star Acquisition Inc. received a nasdaq delisting notice notice regarding other (rules 5450(b)(2)(B)).
“of Listing. As previously disclosed, on November 25, 2024, Global Star Acquisition Inc. (the “Company”) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not in compliance with Nasdaq’s Listing Rule 5450(b)(2)(B) because the Company had not, as of November 18, 2024, maintained a minimum of 1,100,000 publicly held shares, as required under the Nasdaq continued listing standards for The Nasdaq Global Market. Under Nasdaq Listing Rules, the Company had 45 calendar days or until January 9, 2025, to”
Global Star Acquisition Inc. received a nasdaq delisting notice notice regarding shareholders (rules 5450(a)(2)).
“024, we received a notice from the Staff notifying us that the Company is not in compliance with Listing Rule 5450(a)(2) (the “Minimum Public Holders Rule”), which requires the Company to have at least 400 total holders”
Global Star Acquisition Inc. received a nasdaq deficiency notice notice regarding other (rules 5450(b)(2)(B)).
“November 25, 2024, Global Star Acquisition Inc. (the “Company”) received a letter from the listing qualifications department staff (the “Staff”) of The Nasdaq Stock Market (“Nasdaq”) indicating that the Company was not i”
Oklo Inc. received a nyse deficiency notice notice regarding audit committee.
“February 5, 2025, the Company received an official notice of non-compliance from the NYSE (the “NYSE Notice”). The NYSE Notice does not have any immediate effect on the listing of the Company’s common stock, which remain”
STRYVE FOODS, INC. received a nasdaq delisting notice notice regarding stockholders equity (rules 5550(b)(1)).
“February 4, 2025, the Nasdaq Stock Market LLC (“Nasdaq”) notified Stryve Foods, Inc. (the “Company”) that the Nasdaq Hearings Panel (the “Panel”) has determined to delist the Company’s Class A common stock and warrants a”
Beyond Air, Inc. received a nasdaq extension granted notice regarding minimum bid price (rules 5550(a)(2), 5810(c)(3)(A)).
“February 5, 2025, Nasdaq notified the Company that its staff (the “Staff”) determined that the Company is eligible for an additional 180 calendar day period, or until August 4, 2025, to regain compliance. The Staff’s det”
USBC, Inc. received a nyse_american delisting notice notice regarding minimum bid price (rules 1003(f)(v)).
“January 29, 2025, NYSE American LLC (“ NYSE American ” or the “ Exchange ”) publicly announced and provided a notice to Know Labs, Inc. (the “ Company ”) that the NYSE Regulation has suspended trading of, and determined to commence proceedings to delist, the Company’s common stock, par value $0.001 per share (the “ Common Stock ”), from NYSE American. NYSE Regulation has determined that the Company is no longer suitable for listing pursuant to Section 1003(f)(v) of the NYSE American Company Guide (the “ Company Guide ”) due to the low selling price of the Common Stock. The Company has a right”
Flux Power Holdings, Inc. received a nasdaq deficiency notice notice regarding stockholders equity (rules 5550(b)(1)).
“January 31, 2025, Flux Power Holdings, Inc. (the “Company”) received a notice (the “Notice”) from The NASDAQ Stock Market LLC (“Nasdaq”) notifying the Company that based on its stockholders’ equity of $194,000 as reported in its Form 10-K for the fiscal year ended June 30, 2024, the Company is no longer in compliance with Nasdaq Listing Rule 5550(b)(1), which requires the Company to maintain a minimum of $2,500,000 in stockholders’ equity for continued listing on The Nasdaq Capital Market (the “Stockholders’ Equity Requirement”). Pursuant to the Notice, the Company has 45 calendar days from th”
NextCure, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 31, 2025, NextCure, Inc. (the “Company”, “we”, “us”, or “our”) received written notice (the “Notice”) from the Listing Qualifications Department of The Nasdaq Stock Market, LLC (“Nasdaq”) notifying us that the closing price of our common stock over the prior 30 consecutive business days had fallen below $1.00 per share, which is the minimum average closing price required to maintain listing on the Nasdaq Global Select Market under Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Requirement”). In accordance with Nasdaq Listing Rule 5810(c)(3)(A), we have 180 calendar days, or until J”
Omega Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s common stock, par value $0.001 per share (the “Common Stock”), had closed below the $1.00 per share minimum bid price requirement for continued inclusion on The Nasdaq Global Market as set forth in Nasdaq Listing Rule 5450(a)(1) (the “Minimum Bid Price Requirement”). The Notice has no effect at this time on the listing of the Common Stock, which continues to trade on The Nasdaq G”
Solidion Technology Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1), 5810(c)(3)(A)).
“January 29, 2025, the Company received a Staff determination letter that stated the Company had not regained compliance with the Bid Price Rule, and, as a result, the Company’s common stock is now subject to delisting from the Nasdaq Global Market at the opening of business on February 7, 2025. The Company may submit a written request to appeal the Staff’s determination to a Hearings Panel, no later than February 5, 2025, which request would stay the suspension of the Common Stock and the filing of the Form 25-NSE pending the Hearings Panel’s decision. The Company intends to submit a request t”
ALPHATIME ACQUISITION CORP received a nasdaq deficiency notice notice regarding other (rules 5450(a)(2)).
“November 29, 2024, AlphaTime Acquisition Corp (the “ Company ”) received a written notice (the “ Notice ”) from the Listing Qualifications Department (the “ Staff ”) of The Nasdaq Stock Market LLC (“ Nasdaq ”) notifying the Company that the Company is not in compliance with Listing Rule 5450(a)(2) (the “ Minimum Public Holders Rule ”), which requires the Company to have at least 400 total holders for continued listing on The Nasdaq Global Market. An indicator will be displayed with quotation information related to the Company’s securities on listingcenter.nasdaq.com and may be displayed by oth”
ALPHATIME ACQUISITION CORP received a nasdaq extension granted notice regarding shareholders (rules 5450(a)(2)).
“January 29, 2025, Nasdaq issued a notice granting the Company an extension of time to regain compliance with Nasdaq Minimum Total Holders Rule for 180 calendar days, or until May 28, 2025. The terms of the extension are”
Solidion Technology Inc. received a nasdaq delisting notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 29, 2025, the Company received a Staff determination letter that stated the Company had not regained compliance with the Bid Price Rule, and, as a result, the Company’s common stock is now subject to delisting fr”
Omega Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5450(a)(1)).
“January 29, 2025, the Company received a written notice (the “Notice”) from The Nasdaq Stock Market, LLC (“Nasdaq”) notifying the Company that for the last 30 consecutive business days, the bid price for the Company’s co”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.